Stryker holds a smaller portion of the U.S. spinal fusion market with 9.1%, while other companies like Medtronic (37.5%) and Globus Medical (23.9%) have bigger stakes.
“The sale decision appears to be the logical next step when considering Stryker’s performance in this market, and in the long term, it may prove beneficial for the company as it continues to focus on interventional spine products,” GlobalData analyst Aiden Robertson said in the release. “While Stryker does not cover a large section of the market, its competitors are expected to use this opportunity to grow their influence towards what was previously Stryker’s section of the space, which could pose challenges for VB Spine going forward.”
The spinal fusion market is expected to continue growing due to increased prevalence of spinal disorders and advancements in surgical technologies.
